Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first therapy for severe equine asthma
Horses with severe equine asthma struggle to breath, even at rest. Last week, the European Commission granted marketing authorization1 to Boehringer Ingelheim for the new Aservo® EquiHaler® - and horses that suffer from severe equine asthma can now benefit from this new therapy.
While inhaled therapies for the treatment of asthma are common in human health, the approval of the Aservo® EquiHaler® marks an industry first in equine medicine, as until now, there has been no approved corticosteroid inhalant therapy licensed for use in horses with severe equine asthma.
The Aservo® EquiHaler® represents the culmination of over a decade of collaboration between Boehringer Ingelheim’s human pharma and animal health R&D groups. The Respimat™ inhaler used in human respiratory disease is differentiated by the unique Soft Mist™ Technology, which was integrated into the new Aservo® EquiHaler®, allowing medication to be inhaled, deep into the lung. “The inhaler is a prime example of leveraging innovation efforts of both our businesses. This has been a strength in the past and we will expand this in the near future to further increase the delivery of innovative solutions for our patients and customers,” shares Eric Haaksma, Head of R&D, Boehringer Ingelheim Animal Health Business Unit.
The newly approved inhaler is designed specifically for use in horses. It includes an ergonomic handle and dosing lever for ease of user handling, and a nostril adaptor that fits gently inside the nostril of the horse, allowing the horses to easily inhale the medicated mist. The active ingredient in the Aservo® EquiHaler® is the prodrug ciclesonide, which is a corticosteroid that is activated directly in the lung, reducing lower airway inflammation associated with severe equine asthma.
“Treating severe equine asthma can be challenging for veterinarians and horse owners, who struggle to find safe and effective ways to help horses breath,” says Erich Schoett, Global Business Head of Equine for the Boehringer Ingelheim Animal Health Business Unit. “Bringing a new, safe and effective treatment to the market is something that we can really be proud of. It is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation.”
The Aservo® EquiHaler® is expected to be available for veterinarians in the EU in 2020.
For references and notes to editors, please visit: https://www.boehringer-ingelheim.com/press-release/approval-aservo-equihaler-equine-asthma-therapy
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005437/en/
Contact information
Boehringer Ingelheim
Tereza Urbankova
Head of External Communication Animal Health
Boehringer Ingelheim Corporate Center GmbH
P: +49 6132 77-184817
tereza.urbankova@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobileum Earns Industry Recognition from Juniper Research for Its Voice Fraud Prevention and Trust Solutions17.7.2025 10:00:00 EEST | Press release
Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, is proud to announce its recognition as one of the top vendors in Juniper Research’s latest report, Robocall Mitigation & Branded Calling Market: 2025–2030. The study reflects Mobileum’s continued leadership in helping communications service providers (CSPs) combat fraud, safeguard the voice channel, and restore consumer trust through advanced risk mitigation and branded calling solutions. With robocall-related fraud forecast to peak at over $80 billion in 2025, the voice channel faces growing pressure. At the same time, the adoption of branded calling, where verified caller IDs help rebuild consumer trust, is accelerating rapidly. According to Juniper, branded-calling authentication API calls are projected to grow by more than tenfold between 2024 and 2029, indicating a significant shift in the industry toward identity-based frameworks and authenticated communications. Global revenue from branded
Lattice and Mitsubishi Electric Collaborate to Deliver Next-Gen Industrial Automation Experiences17.7.2025 09:30:00 EEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its low power Lattice CertusPro™-NX FPGAs now enable Mitsubishi Electric’s Computerized Numerical Controller (CNC) solutions to bring power efficient and reliable factory automation experiences. This collaboration was announced at the Lattice APAC Tech Summit in Tokyo, where Mitsubishi Electric participated as a guest keynote speaker. Hosted today, Lattice APAC Tech Summit showcased the company’s latest low power FPGA technology with industry leaders including Mitsubishi Electric, Desay, Furukawa AS, Glory LTD, LIPS, and NXP alongside more than 150 customers and partners in the APAC region. Mitsubishi Electric’s industry-leading CNC solutions leverage the cutting-edge interface bridging capabilities of Lattice CertusPro-NX FPGAs to create high accuracy, adaptability, and efficient real-time processing. These features are ideal for a variety of Industrial applications, including machine building, Au
SES Completes Acquisition of Intelsat, Creating Global Multi-Orbit Connectivity Powerhouse17.7.2025 08:30:00 EEST | Press release
SES, a leading space solutions company, today announced the completion of its highly value accretive acquisition of Intelsat, creating a strengthened global satellite operator with an expanded fleet of 120 satellites across two orbits. The newly combined company will leverage its skilled teams with deep vertical expertise to deliver integrated multi-orbit, multi-band satellite and connectivity solutions to businesses and governments around the world, creating a stronger multi-orbit operator with ~60% of revenue in high-growth segments. With a world-class network including approximately 90 geostationary (GEO), nearly 30 medium earth orbit (MEO) satellites, strategic access to low earth orbit (LEO) satellites, and an extensive ground network, SES can now deliver connectivity solutions utilising complementary spectrum bands including C-, Ku-, Ka-, Military Ka-, X-band, and Ultra High Frequency. The expanded capabilities of the combined company will enable it to deliver premium-quality ser
Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss17.7.2025 08:00:00 EEST | Press release
Galderma has revealed positive final data from a phase IV first-of-its-kind trial exploring the benefits of Restylane Lyft or Contour in combination with Sculptrato address the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss.1 These data reinforce that this treatment regimen can effectively improve facial aesthetic appearance with high patient satisfaction over nine months.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716698427/en/ Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude.2-4 Patients may experience facial changes such as dry, dull or sagging skin, a gaunt or hollowed-out facial appearance, or other unwelcome alterations to facial structure and balance.3,4 As the pure-play dermatology category leader, Galderma is spearheading efforts to identify and addres
Global New Material International: Driving a Green Future Through Innovation17.7.2025 05:41:00 EEST | Press release
As global economic integration accelerates, materials science—the foundation of modern industry—is undergoing a profound transformation. Global New Material International Holdings Limited (GNMI) stands at the forefront of this evolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716430383/en/ Colored Building-Integrated Photovoltaic modules developed by CQV, a subsidiary of GNMI. At the recent 2nd Sino-European Corporate ESG Best Practice Conference, GNMI was honored with the “Best Practice in Technological Innovation” award for its outstanding commitment to innovation and green development. The judging panel praised the company’s achievements, noting that “GNMI’s innovations have gained broad international recognition. With a clear strategy focused on green manufacturing and sustainability, the company offers viable solutions to reduce dependence on non-renewable resources while advancing eco-friendly production.” T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom